Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
The British Journal of Dermatology|October 15, 2013
Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1P Rich, M Bourcier, H Sofen, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 22, 2019
A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis managementL Grine, M de la Brassinne, P-D Ghislain, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|August 14, 2020
Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2)J L W Lambert, S Segaert, P D Ghislain, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 12, 2024
Belgian recommendations for managing psoriasis in a changing treatment landscapeR Speeckaert, A F Nikkels, J Lambert, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2020
Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasisJ F Merola, P-D Ghislain, J N Dauendorffer, et al.Dermatology (Basel, Switzerland)|December 11, 1999
The use of itraconazole to treat cutaneous fungal infections in childrenA K Gupta, S Nolting, Y de Prost, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 13, 2022
Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA studyM Augustin, P G Sator, R von Kiedrowski, et al.The British Journal of Dermatology|April 10, 2010
A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE studyD Thaçi, J-P Ortonne, S Chimenti, et al.The British Journal of Dermatology|January 11, 2013
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upK A Papp, C E M Griffiths, K Gordon, et al.The British Journal of Dermatology|April 25, 2019
Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III studyD Thaçi, K Papp, D Marcoux, et al.Pageof 4